Literature DB >> 9303513

Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C.

M L Shiffman1, C M Hofmann, E B Thompson, A Ferreira-Gonzalez, M J Contos, A Koshy, V A Luketic, A J Sanyal, A S Mills, C T Garrett.   

Abstract

The present study was conducted to evaluate the relationship between biochemical, virological, and histological response during the course of interferon therapy. Ninety consecutive patients with well-documented chronic hepatitis C virus (HCV) were treated with 5 MU of interferon alfa-2b three times weekly for 6 months. Liver biopsy was performed, and serum HCV RNA titer was measured before and at the completion of interferon treatment. Normalization of serum alanine transaminase (ALT) concentration (biochemical response) was observed in 50% of patients. In these patients, Knodell score declined significantly from 9.6 +/- 0.5 to 5.0 +/- 0.5 (P < .01), and 75% became HCV RNA negative. The remaining patients (50%) were biochemical nonresponders; mean Knodell score declined from 9.6 +/- 0.5 to 7.7 +/- 0.5 (P < .01), and 11% became HCV RNA negative. For both biochemical responders and nonresponders, the decline in Knodell score was confined to the components of hepatic inflammation (piecemeal necrosis + lobular + portal inflammation); no change in fibrosis was observed. Hepatic inflammation declined by 5 points or more in 69% of biochemical responders and 48% of biochemical nonresponders, and by at least 50% from pretreatment values in 74% and 38% of biochemical responders and biochemical nonresponders, respectively. For all patients (both biochemical responders and nonresponders) who remained viremic at the conclusion of interferon therapy, the reduction in hepatic inflammation was a linear function of the decline in HCV RNA titer. We conclude that more than one third of patients who had no biochemical response after 6 months of interferon therapy achieved a similar improvement in hepatic histology as was observed in patients with biochemical response. This improvement in hepatic histology appeared to correlate with a reduction in HCV RNA titer, especially in patients who remained viremic.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9303513     DOI: 10.1002/hep.510260335

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  24 in total

Review 1.  Treatment of hepatitis C. The 2002 French consensus.

Authors:  D Dhumeaux; P Marcellin; E Lerebours
Journal:  Gut       Date:  2003-12       Impact factor: 23.059

2.  Hepatitis C Virus Therapy-related Skin Manifestations.

Authors:  Brett E Fortune; Shayla Francis; Lisa M Forman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-05

3.  Improved Survival Among all Interferon-α-Treated Patients in HCV-002, a Veterans Affairs Hepatitis C Cohort of 2211 Patients, Despite Increased Cirrhosis Among Nonresponders.

Authors:  Myrna L Cozen; James C Ryan; Hui Shen; Ramsey Cheung; David E Kaplan; Christine Pocha; Norbert Brau; Ayse Aytaman; Warren N Schmidt; Marcos Pedrosa; Bhupinderjit S Anand; Kyong-Mi Chang; Timothy Morgan; Alexander Monto
Journal:  Dig Dis Sci       Date:  2016-04-08       Impact factor: 3.199

Review 4.  The management of patients awaiting liver transplantation.

Authors:  Ka-Kit Li; James Neuberger
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-10-06       Impact factor: 46.802

5.  The course of elderly patients with persistent hepatitis C virus infection without hepatocellular carcinoma.

Authors:  Kazuyuki Mizuno; Hidenori Toyoda; Satoshi Yasuda; Toshifumi Tada; Takashi Kumada; Yasuhiro Sone; Junko Tanaka
Journal:  J Gastroenterol       Date:  2019-06-03       Impact factor: 7.527

6.  Dialysis reduces portal pressure in patients with chronic hepatitis C.

Authors:  Sandeep Khurana; Thomas Simcox; William Twaddell; Cinthia Drachenberg; Mark Flasar
Journal:  Artif Organs       Date:  2010-07       Impact factor: 3.094

Review 7.  Hepatitis C virus infection--pathobiology and implications for new therapeutic options.

Authors:  Gary L Davis; Kris Krawczynski; Gyongyi Szabo
Journal:  Dig Dis Sci       Date:  2007-02-27       Impact factor: 3.199

8.  Normalization of markedly elevated alpha-fetoprotein in a virologic nonresponder with HCV-related cirrhosis.

Authors:  David F Stein; Malay Myaing
Journal:  Dig Dis Sci       Date:  2002-12       Impact factor: 3.199

Review 9.  Chronic hepatitis C: treatment of pegylated interferon/ribavirin nonresponders.

Authors:  Mitchell L Shiffman
Journal:  Curr Gastroenterol Rep       Date:  2006-02

10.  Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial.

Authors:  Mitchell L Shiffman; Chihiro Morishima; Jules L Dienstag; Karen L Lindsay; John C Hoefs; William M Lee; Elizabeth C Wright; Deepa Naishadham; Gregory T Everson; Anna S Lok; Adrian M Di Bisceglie; Herbert L Bonkovsky; Marc G Ghany
Journal:  Gastroenterology       Date:  2009-09-10       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.